Key Findings
Regeneron Pharmaceuticals unveiled its initial clinical results for Ubamatamab, an investigational MUC16×CD3 bispecific antibody, in patients with advanced low-grade serous ovarian cancer (LGSOC) at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting. The data unequivocally demonstrated that Ubamatamab monotherapy achieved an exceptionally high objective response rate (ORR) of 73% in advanced LGSOC, coupled with durable anti-tumor activity. This represents a significant breakthrough for LGSOC patients who often exhibit resistance to existing therapies.
Technical / Clinical Details
Ubamatamab is an innovative bispecific antibody designed to concurrently bind to both the MUC16 antigen, highly expressed on the surface of cancer cells, and the CD3 receptor on T-cells. Functioning as a ‘T-cell engager,’ it effectively bridges T-cells to MUC16-expressing cancer cells, thereby activating the T-cells to specifically eliminate tumor cells. The presented data originate from the ongoing Phase 1/2 study (NCT03564340), which is evaluating Ubamatamab as both a monotherapy and in combination with Regeneron’s PD-1 antibody, Libtayo (cemiplimab). Notably, eight out of eleven (73%) advanced LGSOC patients receiving Ubamatamab 800mg monotherapy achieved an objective response. Beyond this impressive ORR, many responses demonstrated prolonged duration, indicating the potential for long-term disease control. The safety profile was manageable, with concerns typically associated with bispecific antibodies appropriately addressed.
Background & Context
Low-grade serous ovarian cancer (LGSOC) is a relatively rare subtype of ovarian cancer that, while slower-growing than other ovarian cancers, is characterized by its poor response to chemotherapy. Existing treatment options are limited, and the prognosis for patients with advanced or recurrent LGSOC remains challenging. MUC16 is widely expressed on ovarian cancer cells, making it an attractive target, but previous single-target therapies have yielded insufficient efficacy. Bispecific antibodies like Ubamatamab, by directly redirecting T-cells to tumors, offer a potent new approach to powerfully activate the immune system and potentially benefit patients who have failed conventional treatments, generating considerable excitement in the gynecologic oncology field.
Strategic Significance & Outlook
The 73% ORR observed in Ubamatamab’s initial clinical results holds the potential to significantly alter the treatment landscape for advanced LGSOC. This promising data will vigorously support further development programs, particularly the expedited progression into later-stage clinical trials. If approved, Ubamatamab is expected to become a crucial new therapeutic option for LGSOC patients who currently face severely limited choices. Regeneron will continue to evaluate Ubamatamab in combination with Libtayo, anticipating further enhancements in therapeutic efficacy. This achievement broadly demonstrates the potential of T-cell engagers in gynecologic cancers and could influence research into their application for other MUC16-expressing solid tumors, expanding the impact of this innovative modality.
Source: https://pharmacally.com/ubamatamab-lgsoc-durable-responses/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
